Talk:MeNZB

Ěthis was an effective immunisation :]


 * yeah it really was.


 * har har.

219.89.103.84 02:51, 2 September 2007 (UTC)HAHHA

External links modified (January 2018)
Hello fellow Wikipedians,

I have just modified 2 external links on MeNZB. Please take a moment to review my edit. If you have any questions, or need the bot to ignore the links, or the page altogether, please visit this simple FaQ for additional information. I made the following changes:
 * Added tag to http://www.health.govt.nz/news-media/media-releases/menzb-vaccine-helped-curb-epidemic
 * Added archive https://web.archive.org/web/20041014220750/http://www.immunise.moh.govt.nz/MeNZB.html to http://www.immunise.moh.govt.nz/MeNZB.html
 * Added tag to http://www.menzb.com/menzb-vaccine.htm
 * Added archive https://web.archive.org/web/20061001095532/http://www.bsa.govt.nz/decisions/2005/2005-104.htm to http://www.bsa.govt.nz/decisions/2005/2005-104.htm

When you have finished reviewing my changes, you may follow the instructions on the template below to fix any issues with the URLs.

Cheers.— InternetArchiveBot  (Report bug) 18:39, 23 January 2018 (UTC)

Bexsero (= 4CMenB = MenB-4C) protects from Gonorrhea
https://en.wikipedia.org/wiki/Gonorrhea

https://en.wikipedia.org/wiki/MeNZB

--

https://pubmed.ncbi.nlm.nih.gov/29048985/

2018 May 4

The recent discovery that meningococcal group B OMVs may protect against the related Neisseria species N.gonorrhoeae. There are 2 OMV-containing group B vaccines available, the new recombinant protein-based Bexsero® developed by Novartis and VA-MENGOC-BC® developed by the Finlay institute in Cuba.

Also, a third group B vaccine based on two recombinant factor H binding proteins (Trumenba®, Pfizer), has recently been licenced but it does not include OMV.

--

https://www.immunize.org/askexperts/experts_meningococcal_b.asp#recommendations


 * Available data indicate that protective antibody levels wane in most recipients within 1–2 years of completion of the primary series.


 * Bexsero (MenB-4C, GSK) is a 2-dose series with doses given at least 1 month apart.


 * Evidence to date suggests no impact of MenB vaccine on meningococcal B carriage (may protect an individual from invasive disease but is unlikely to impact transmission of the bacteria to others)


 * Approved ages 10–25 years in USA.

In Finland approved for all ages including >50 years:

https://laakeinfo.fi/Medicine.aspx?m=17572&i=GLAXOSMITHKLINE_BEXSERO

---

https://www.nature.com/articles/s41541-021-00388-3

Title: Looking beyond meningococcal B with the 4CMenB vaccine: the Neisseria effect

29 October 2021

Real-world evidence showed risk reductions of 69% for meningococcal serogroup W clonal complex 11 disease and 40% for gonorrhea after 4CMenB immunization.

--

https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00812-4/fulltext

Title: Effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhoea: a retrospective observational study

April 12, 2022

Complete MenB-4C vaccination series was 40% (95% CI 23–53) effective against gonorrhoea and partial MenB-4C vaccination series was 26% (12–37) effective.

Complete vaccination = two MenB-4C doses administered 30–180 days apart.

--

https://reference.medscape.com/drug/trumenba-bexsero-meningococcal-group-B-vaccine-999974

Bexsero. 0.5 mL IM as a 2-dose series administered at least 1 month apart

ACIP recommendations for at risk adults

Booster dose: Administer 1 year after primary series completed and repeat booster dose every 2-3 yr if risk remains

At risk individuals include e.g. Microbiologists routinely exposed to Neisseria meningitidis

Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.

--

https://gskpro.com/en-gb/products/bexsero/real-world-evidence/

Study design: 3-year observational study

Bexsero was introduced for all infants in the UK in September 2015.

Infants were administered the vaccine at 2, 4 and 12 months, which resulted in a 75% reduction in meningitis B incidence in all fully eligible children in England. incidence rate ratio, 0.25; 95% CI, 0.19 to 0.36).

--

https://www.medicines.org.uk/emc/product/5168

Intervals between Primary Doses: Not less than 1 month or 2 months, depending on age.

There are no data in adults above 50 years of age.

91.159.188.253 (talk) 22:29, 15 June 2022 (UTC)